System and method for outcome tracking and analysis

Abstract

Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

What is claimed is: 
     
         1 . A system for tracking and analysis of cancer treatment and outcome information, the system comprising:
 at least one processor operatively connected to a memory, the at least one processor when executing is configured to:
 receive treatment and outcome information associated with a patient from at least one user; 
 organize the treatment and the outcome information according to one or more of alteration, affected gene, affected pathway, tumor type, and treatment; 
 generate outcome summary information including course of treatment displays over time; and 
 communicate the outcome summary information to the at least one user. 
   
     
     
         2 . The system according to  claim 1 , wherein the treatment information includes any one or more of drugs, therapeutics, named drugs, named therapeutics, drug cocktails, drug combinations, radiation, and surgery. 
     
     
         3 . The system according to  claim 1 , wherein the outcome information includes information regarding a status of a patient's cancer. 
     
     
         4 . The system according to  claim 3 , wherein the status of the patient's cancer includes one or more of complete response, partial response, stable disease, and progressive disease. 
     
     
         5 . The system according to  claim 1 , wherein the course of treatment includes information regarding how patient is responding to treatment over time. 
     
     
         6 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on information related to genomic alteration. 
     
     
         7 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on information related to affected gene identified in a cancer. 
     
     
         8 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on information related to treatment. 
     
     
         9 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on related to tumor type. 
     
     
         10 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on information relating to a combination of at least two or more of a group comprising alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         11 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on information related to at least one of alteration, affected gene, affected pathway, tumor type, and treatment for a patient's cancer, wherein the analysis component is configured to aggregate responsive information according to one or more of alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         12 . The system according to  claim 11 , wherein the analysis component is configured to aggregate similar patients within classes of genomic alterations. 
     
     
         13 . The system according to  claim 12 , wherein the classes of genomic alterations include alterations in a specified domain of a gene. 
     
     
         14 . The system according to  claim 13 , wherein the domain includes at least a kinase domain of the gene. 
     
     
         15 . The system according to  claim 14 , wherein the gene includes BRAF, and the specific domains include at least one of kinase, BRAF V600E, and BRAF V600K. 
     
     
         16 . The system according to  claim 11 , wherein the analysis component is configured to aggregate alteration information according to pathways affected by respective alterations. 
     
     
         17 . The system according to  claim 11 , where the analysis component is configured to aggregate similar patient information based on functional similarity of identified alterations, which can be determined for distinct mutations having functionally similar characteristics in the cancer cells. 
     
     
         18 - 25 . (canceled) 
     
     
         26 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to compare a current patient record to existing treatment information. 
     
     
         27 . The system according to  claim 26 , wherein the existing treatment information includes at least one of alteration, affected gene, affected pathway, tumor type, and one or more treatments. 
     
     
         28 . The system according to  claim 27 , wherein the analysis component is configured to identify similar patients based on information in the current patient record, wherein identifying the similar patients includes determining a match between the current patient record and at least one of alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         29 . The system according to  claim 1 , further comprising an analysis component executed by the at least one processor configured to identify similar patients based on user selection of at least one of tumor type, alteration, affected gene, and treatment. 
     
     
         30 . The system according to  claim 29 , wherein the analysis component is configured to filter a grouping of similar patients based on additional specification of at least one of alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         31 - 48 . (canceled) 
     
     
         49 . A computer implemented method for tracking and analysis of cancer treatment and outcome information, the method comprising:
 receiving, by a computer system, treatment and outcome information associated with a patient from at least one user;   organizing, by the computer system, the treatment and the outcome information according to one or more of alteration, affected gene, affected pathway, tumor type, and treatment;   generating, by the computer system, outcome summary information including course of treatment displays over time; and   communicating, by the computer system, the outcome summary information to the at least one user.   
     
     
         50 . The method according to  claim 49 , wherein the treatment information includes any one or more of drugs, therapeutics, named drugs, named therapeutics, drug cocktails, drug combinations, radiation, and surgery. 
     
     
         51 . The method according to  claim 49 , wherein the outcome information includes information regarding a status of a patient's cancer. 
     
     
         52 . The method according to  claim 51 , wherein the status of the patient's cancer includes one or more of complete response, partial response, stable disease, and progressive disease. 
     
     
         53 . The method according to  claim 49 , wherein the course of treatment includes information regarding how patient is responding to treatment. 
     
     
         54 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on information related to genomic alteration. 
     
     
         55 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on information related to affected gene identified in a cancer. 
     
     
         56 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on information related to treatment. 
     
     
         57 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on related to tumor type. 
     
     
         58 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on information relating to a combination of at least two or more of a group comprising alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         59 . The method according to  claim 49 , further comprising:
 identifying, by the computer system, similar patients based on information related to at least one of alteration, affected gene, affected pathway, tumor type, and treatment for a patient's cancer; and   aggregating, by the computer system, responsive information according to one or more of alteration, affected gene, affected pathway, tumor type, and treatment.   
     
     
         60 . The method according to  claim 59 , further comprising aggregating, by the computer system, similar patients within classes of alterations. 
     
     
         61 . The method according to  claim 60 , wherein the classes of alteration include alterations in a specified domain of a gene. 
     
     
         62 . The method according to  claim 61 , wherein the domain includes at least a kinase domain of the gene. 
     
     
         63 . The method according to  claim 62 , wherein the gene includes BRAF, and the specific domains include at least one of kinase, BRAF V600E, and BRAF V600K. 
     
     
         64 . The method according to  claim 59 , further comprising aggregating, by the computer system, alteration information according to pathways affected by respective alterations. 
     
     
         65 . The method according to  claim 59 , further comprising aggregating, by the computer system, similar patient information based on functional similarity of identified alterations, which can be determined for distinct mutations having functionally similar characteristics in the cancer cells. 
     
     
         66 - 73 . (canceled) 
     
     
         74 . The method according to  claim 49 , further comprising comparing, by the computer system, a current patient record to existing treatment information. 
     
     
         75 . The method according to  claim 74 , wherein the existing treatment information includes at least one of alteration, affected gene, affected pathway, tumor type, and one or more treatments. 
     
     
         76 . The method according to  claim 74 , further comprising identifying, by the computer system, similar patients based on information in the current patient record, wherein identifying the similar patients includes determining a match between the current patient record and at least one of alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         77 . The method according to  claim 49 , further comprising identifying, by the computer system, similar patients based on user selection of at least one of tumor type, alteration, genes, and treatment. 
     
     
         78 . The method according to  claim 77 , further comprising filtering, by the computer system, a grouping of similar patients based on additional specification of at least one of alteration, affected gene, affected pathway, tumor type, and treatment. 
     
     
         79 - 96 . (canceled) 
     
     
         97 . The system according to  claim 13 , wherein the domain includes at least an ATP binding pocket domain. 
     
     
         98 . The system according to  claim 97 , where the analysis component is configured to aggregate information associated with patients having at least one alteration within the ATP binding pocket domain. 
     
     
         99 . The system according to  claim 98 , wherein the analysis component is configured to aggregate information associated with patients having at least one alteration within the ATP binding pocket domain for a specified gene. 
     
     
         100 . The system according to  claim 98 , wherein the analysis component is configured to aggregation information associated with patients having at least one alteration within the ATP binding pocket domain for a plurality of genes. 
     
     
         101 . The system according to  claim 12 , wherein the classes of alterations includes at least a tumor suppressor gene alteration class. 
     
     
         102 . The system according to  claim 101 , wherein the analysis component is configured to aggregate the responsive information based on patients having at least one alteration within the tumor suppressor gene alteration class. 
     
     
         103 . The system according to  claim 102 , wherein the analysis component is configured to aggregate the responsive information based on a specific gene. 
     
     
         104 . The system according to  claim 103 , wherein the analysis component is configured to aggregate the responsive information based on a plurality of specified genes. 
     
     
         105 . The system according to  claim 11 , wherein the analysis component is configured to aggregate the responsive information based on at least one gene identified within a pathway. 
     
     
         106 . The system according to  claim 105 , wherein the analysis component is configured to aggregate the responsive information based on a plurality of genes identified within the pathway. 
     
     
         107 . The system according to  claim 1 , wherein the system is configured to access or receive anonymized patient data from a plurality of data sources, and wherein the system further comprises an analysis component executed by the at least one processor configured to identify similar patients to a current patient based on information on the current patient's cancer.